165 related articles for article (PubMed ID: 25172964)
1. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N
Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
4. AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression.
Chen Y; Lee CH; Tseng BY; Tsai YH; Tsai HW; Yao CL; Tseng SH
Anticancer Res; 2018 Mar; 38(3):1445-1454. PubMed ID: 29491070
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
8. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
[TBL] [Abstract][Full Text] [Related]
9. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Chresta CM; Davies BR; Hickson I; Harding T; Cosulich S; Critchlow SE; Vincent JP; Ellston R; Jones D; Sini P; James D; Howard Z; Dudley P; Hughes G; Smith L; Maguire S; Hummersone M; Malagu K; Menear K; Jenkins R; Jacobsen M; Smith GC; Guichard S; Pass M
Cancer Res; 2010 Jan; 70(1):288-98. PubMed ID: 20028854
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of TORC1/2 in multiple myeloma.
Maiso P; Liu Y; Morgan B; Azab AK; Ren P; Martin MB; Zhang Y; Liu Y; Sacco A; Ngo H; Azab F; Quang P; Rodig SJ; Lin CP; Roccaro AM; Rommel C; Ghobrial IM
Blood; 2011 Dec; 118(26):6860-70. PubMed ID: 22045983
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
12. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
Li Q; Song XM; Ji YY; Jiang H; Xu LG
Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
Huang S; Yang ZJ; Yu C; Sinicrope FA
J Biol Chem; 2011 Nov; 286(46):40002-12. PubMed ID: 21949121
[TBL] [Abstract][Full Text] [Related]
14. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.
Xu DQ; Toyoda H; Yuan XJ; Qi L; Chelakkot VS; Morimoto M; Hanaki R; Kihira K; Hori H; Komada Y; Hirayama M
Exp Cell Res; 2018 Apr; 365(2):177-184. PubMed ID: 29499203
[TBL] [Abstract][Full Text] [Related]
16. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A
Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120
[TBL] [Abstract][Full Text] [Related]
17. Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.
Xu DQ; Toyoda H; Qi L; Morimoto M; Hanaki R; Iwamoto S; Komada Y; Hirayama M
Biochem Biophys Res Commun; 2018 May; 499(3):425-432. PubMed ID: 29571732
[TBL] [Abstract][Full Text] [Related]
18. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
19. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
